Revumenib conferred complete remission or complete remission with partial hematologic recovery in nearly one-quarter of patients with two acute leukemia subtypes, according to the agent’s manufacturer.
Topline data from the pivotal phase 2 AUGMENT-101 trial suggested an acceptable safety profile among individuals with advanced acute leukemias with KMT2A rearrangements who received revumenib (SNDX-5613, Syndax Pharmaceuticals) — an oral small-molecule menin inhibitor. FDA previously granted breakthrough therapy designation to the investigational therapy for treatment of adults and